Testing the SurVaxM Vaccine for Lung Cancer Prevention

NCT07169617 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

NIH

Sponsor class

Conditions

Lung Carcinoma

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Montanide ISA 51 VG
OTHER: Questionnaire Administration
BIOLOGICAL: Sargramostim
BIOLOGICAL: SVN53-67/M57-KLH Peptide Vaccine

Sponsor

National Cancer Institute (NCI)